Finance

Lists
Why is OCGN down २.२७%?
Dive Deeper
OCGN:NASDAQ
Ocugen Inc
US$ ०.९५
-२.२७%
(-०.०२२) 1D
US$ ०.९५
-०.०१% (-०.०००१०)
After hours
Closed: नोभेम्बर १०, १६:००:०० GMT-५  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for OCGN...
Open
US$ ०.९९
High
US$ १.०६
Low
US$ ०.९२
Mkt. cap
३२.३० करोड
Avg. vol.
६८.९९ लाख
Volume
७२.८७ लाख
52-wk high
US$ २.७२
52-wk low
US$ ०.६९
EPS
-US$ ०.३०
Beta
२.०४
Shares outstanding
३३.९३ करोड
No. of employees
११६
Open
US$ ०.९९
High
US$ १.०६
Low
US$ ०.९२
Mkt. cap
३२.३० करोड
Avg. vol.
६८.९९ लाख
Volume
७२.८७ लाख
52-wk high
US$ २.७२
52-wk low
US$ ०.६९
EPS
-US$ ०.३०
Beta
२.०४
Shares outstanding
३३.९३ करोड
No. of employees
११६
News stories
From web sources and news partners
Yahoo Finance
Yahoo Finance
·
१ घण्टा पहिले
OCGN : 8-K : Corporate Changes & Voting Matters
News Corp
News Corp
·
३ घण्टा पहिले
Ocugen Inc. stock falls Tuesday, underperforms market
Investing.com India
Investing.com India
·
१२ घण्टा पहिले
Form 8K Ocugen, Inc For: 10 November By Investing.com
Investing.com
Investing.com
·
१४ घण्टा पहिले
Ocugen licenses gene therapy OCU400 to Celairis for Asia-Pacific
About Ocugen Inc
CEOShankar Musunuri
Employees११६
Founded२०१३
HeadquartersMalvern, पेन्सिलभेनिया, संयुक्त राज्य अमेरिका
SectorHealth Care
Industry-
Websiteocugen.com
Analyst ratings
Based on 5 analysts giving stock ratings to OCGN in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for OCGN in the last 3 months.
Highest
Current US$ ०.९५
US$ १२.०० (+१,१६३.१६%)
Average
US$ १०.२० (+९७३.६८%)
Lowest
US$ ८.०० (+७४२.११%)
Analyst
Recommendation
Action
Price target
Projected
Date
Whitney Ijem
Canaccord Genuity
Buy
Maintained
US$ ११.००
+१,०५७.९%
11/04/2026
Swayampakula Ramakanth
H.C. Wainwright
Buy
Reiterated
US$ १०.००
+९५२.६%
11/05/2026
Leland Gershell
Oppenheimer
Buy
Reiterated
US$ १०.००
+९५२.६%
09/29/2026
Robert LeBoyer
Noble Financial
Buy
Reiterated
US$ १२.००
+१,१६३.२%
09/28/2026
Michael Okunewitch
Maxim Group
Buy
Reiterated
US$ ८.००
+७४२.१%
09/16/2026
Daniil Gataulin
Chardan Capital
Buy
Reiterated
US$ ७.००
+६३६.८%
05/07/2026
Elemer Piros
Lucid Capital
Buy
Maintained
US$ २२.००
+२,२१५.८%
03/11/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
२०२५ डिसेम्बर
२०२६ मार्च
२०२६ जुन
२०२६ सेप्टेम्बर
Revenue
-१.९३ लाख
१५.३३ लाख
१४.८८ लाख
१९.५१ लाख
Cost of goods sold
१.०७ करोड
१.१३ करोड
१.०७ करोड
१.२५ करोड
Cost of revenue
१.०७ करोड
१.१३ करोड
१.०७ करोड
१.२५ करोड
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
६१.३३ लाख
८१.१७ लाख
७२.४२ लाख
७२.०४ लाख
Operating expense
६१.३३ लाख
८१.१७ लाख
७२.४२ लाख
७२.०४ लाख
Total operating expenses
१.६८ करोड
१.९४ करोड
१.७९ करोड
१.९७ करोड
Operating income
-१.७० करोड
-१.७८ करोड
-१.६४ करोड
-१.७८ करोड
Other non operating income
४.७७ लाख
-१.५० लाख
-१९.६९ लाख
१.६६ करोड
EBT including unusual items
-१.७७ करोड
-१.९२ करोड
-२.४९ करोड
-३५.९८ लाख
EBT excluding unusual items
-१.७७ करोड
-१.९२ करोड
-२.२५ करोड
-३५.९८ लाख
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-१.७७ करोड
-१.९२ करोड
-२.४९ करोड
-३५.९८ लाख
Net profit margin
९,१७४.०९%
-१,२५०.९५%
-१,६७१.८४%
-१८४.४२%
Earnings per share
-०.०६
-०.०६
-०.०६
-०.०६
Interest and investment income
१.४४ लाख
१.३२ लाख
३.९५ लाख
६.४९ लाख
Interest expense
-१३.३२ लाख
-१३.२० लाख
-४४.७६ लाख
-३०.९० लाख
Net interest expenses
-११.८८ लाख
-११.८८ लाख
-४०.८१ लाख
-२४.४१ लाख
Depreciation and amortization charges
-
-
-
-
EBITDA
-१.६४ करोड
-१.७२ करोड
-१.५९ करोड
-१.७२ करोड
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google एपहरू